TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32267934
Drug: Triglycerides 2.0-2.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triglycerides 2.0-2.9 mmol/L (177-265 mg/dL)
Study: 32267934
Drug: Triglycerides 3.0-3.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triglycerides 3.0-3.9 mmol/L (266-353 mg/dL)
Study: 32267934
Drug: Triglycerides 4.0-4.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triglycerides 4.0-4.9 mmol/L (354-442 mg/dL)
Study: 32267934
Drug: Triglycerides ≥5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triglycerides ≥5 mmol/L (≥443 mg/dL)
Study: 32267934
Drug: Plasma triglycerides
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma triglycerides <2.0 mmol/L (77 mg/dL)
Study: 32267934
Drug: Plasma triglycerides
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma triglycerides 2.0-4.9 mmol/L (177-442 mg/dL)
Study: 32267934
Drug: Plasma triglycerides
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma triglycerides ≥5.0 mmol/L (443 mg/dL)
Study: 32267934
Drug: Remnant cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remnant cholesterol <0.5 mmol/L (19 mg/dL)
Study: 32267934
Drug: Remnant cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remnant cholesterol 0.5-1.4 mmol/L (19-57 mg/dL)
Study: 32267934
Drug: Remnant cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remnant cholesterol ≥1.5 mmol/L (58 mg/dL)
Study: 36319912
Drug: Nefopam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam (20 mg in 100 mL normal saline)
Study: 36319912
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline (100 mL)
Study: 36220712
Drug: Adoptive Immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adoptive Immunotherapy with CD25/CD71 allodepleted donor T cells (ADTs)
Study: 32147032
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections of 200000 IU vitamin D supplement (two injections, one at week 0 and another at week 4)
Study: 35788212
Drug: Control limb
Normalized name: BANDAGE TUBULAR ELAST TUBIFAST LG LIMB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control limb (no treatment)
Study: 35766592
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg propofol (group P)
Study: 35766592
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg lidocaine 2% (group L)
Study: 35919499
Drug: Traditional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional group (50 patients) receiving conventional treatment
Study: 32819331
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) program covering six techniques in 4 sessions (30 min each), with or without pharmacotherapy.
Study: 32819331
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not specified in detail, but implied to be standard care or pharmacotherapy).
Study: 35082179
Drug: Laser-grooved treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser-grooved treatment
Study: 35082179
Drug: Sulfuric-acid-etched treatment
Normalized name: Sulfuric Acid
DrugBank: Sulfuric acid (DB11309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfuric-acid-etched treatment
Study: 35082179
Drug: Sandblasted treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandblasted treatment
Study: 34733185
Drug: Music Assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music Assisted Relaxation (MAR) protocol, a music therapy technique composed of entrained live music combined with a guided relaxation and/or the use of imagery
Study: 35801801
Drug: Oral sulfate
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sulfate tablet (OST)
Study: 32157599
Drug: DB-020 (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: DB-020 (sodium thiosulfate pentahydrate in 1% sodium hyaluronate) administered via intratympanic injection
Study: 32080811
Drug: 650 mg
Normalized name: bran 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg of PL-ASA in fasted state
Study: 32080811
Drug: 650 mg
Normalized name: bran 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg of PL-ASA in fed state
Study: 35946981
Drug: Tretinoin 0.05%
Normalized name: TRETINOIN 0.05% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin 0.05% lotion (Altreno)
Study: 35946981
Drug: Generic 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic 0.05% cream
Study: 35337317
Drug: Objective Structured
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Objective Structured Clinical Examination (OSCE) assessment method for Kampo medicine
Study: 32350185
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% zinc oxide paste, applied trice daily after food for the entire treatment period, initiated 2 days prior to radiotherapy.
Study: 32350185
Drug: Improvised zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improvised zinc preparation (1%), applied trice daily after food for the entire treatment period, initiated 2 days prior to radiotherapy.
Study: 32350185
Drug: Improvised zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improvised zinc preparation (1%)
Study: 32350185
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment offered by cancer hospital (Control group)
Study: 36062848
Drug: Dilemma‐focused therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilemma‐focused therapy
Study: 33897217
Drug: Preferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preferred treatment for people with depression
Study: 34281611
Drug: Lower Extremity
Normalized name: lymphedema garments, lower extremity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower Extremity Constraint-Induced Movement Therapy (LE-CIT) for 2.5 h/day for 15 consecutive days, including intensive supervised training, shaping strategy for motor training, and a transfer package (plus 30 min).
Study: 36359533
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy in the cervical spine and diaphragm, in combination with breathing reeducation exercises
Study: 36359533
Drug: Cervical spine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical spine manual therapy or usual physical therapy care
Study: 32712663
Drug: Preemptive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive therapy (PET) with valganciclovir for 100 days
Study: 32697707
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg over 45 min; n = 12)
Study: 36474770
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg S201086/GLPG1972
Study: 36474770
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg S201086/GLPG1972
Study: 36474770
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg S201086/GLPG1972
Study: 34414430
Drug: No rate
Approvals — FDA: no, EMA: no, PMDA: no
Description: No rate control drugs
Study: 33950868
Drug: Anterior approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior approach injection (54 patients)
Study: 33950868
Drug: Posterior approach
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior approach injection (41 patients)
Study: 33162294
Drug: Slope-configured implants
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Slope-configured implants (test group)
Study: 33162294
Drug: Regular-configured implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular-configured implants (control group)
Study: 35781462
Drug: 1‰ PL‐5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1‰ PL‐5 spray
Study: 35781462
Drug: 2‰ PL‐5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2‰ PL‐5 spray
Study: 35781462
Drug: 4‰ PL‐5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‰ PL‐5 spray
Study: 35781462
Drug: PL‐5 spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: PL‐5 spray
Study: 33988881
Drug: Vismodegib treatment
Normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Vismodegib treatment
Study: 35801741
Drug: 4‐hour 1 + 2L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐hour 1 + 2L bowel preparation regimen
Study: 35801741
Drug: 6‐hour 1 + 2L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6‐hour 1 + 2L bowel preparation regimen
Study: 35801741
Drug: 4‐hour 0 + 2L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐hour 0 + 2L bowel preparation regimen
Study: 34724085
Drug: Standard-dose radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose radiotherapy (3.0 Gy total, 0.5 Gy twice weekly)
Study: 34724085
Drug: Very-low-dose radiotherapy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very-low-dose radiotherapy (0.3 Gy total, 0.05 Gy twice weekly)
Study: 33374006
Drug: Rifapentine (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifapentine (specific dosage not mentioned)
Study: 32056507
Drug: CT-based implant
Normalized name: Ct-053 free base
DrugBank: Ningetinib (DB16256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-based implant motion analysis (CTMA) using surface anatomy of the pelvis
Study: 32056507
Drug: CT-based implant
Normalized name: Ct-053 free base
DrugBank: Ningetinib (DB16256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-based implant motion analysis (CTMA) using beads
Study: 32056507
Drug: CT-based implant
Normalized name: Ct-053 free base
DrugBank: Ningetinib (DB16256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-based implant motion analysis (CTMA)
Study: 32297782
Drug: 6 mg/mL
Normalized name: phenol 6 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/mL nicotine e‐liquid
Study: 32297782
Drug: 12 mg/mL
Normalized name: niacin 12 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg/mL nicotine e‐liquid
Study: 32122230
Drug: Vortioxetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (10 mg b.i.d.)
Study: 33739883
Drug: HDR‐2 (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDR‐2 (900 mg per day for 8 weeks)
Study: 33739883
Drug: Placebo (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (900 mg per day for 8 weeks)
Study: 35760720
Drug: Evolocumab (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (140 mg every 2 weeks)
Study: 35872448
Drug: Real tDCS
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real tDCS stimulation (anodal electrical stimulation at 2 mA for 20 min once daily for 7 days)
Study: 33550243
Drug: Enteral DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral DHA supplementation (60 mg/kg/day)
Study: 32859615
Drug: Exercise and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise and Metformin
Study: 33493373
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with an opioid
Study: 32352250
Drug: Loteprednol etabonate
Normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loteprednol etabonate gel 0.5%
Study: 32352250
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone acetate suspension 1%
Study: 34404290
Drug: Pimavanserin augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimavanserin augmentation
Study: 34404290
Drug: Pimavanserin augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimavanserin augmentation of antipsychotics
Study: 32869527
Drug: Oral HIV
Normalized name: HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HIV self-tests (HIVST) distributed in intervention clusters
Study: 33574125
Drug: Imeglimin (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imeglimin (1,000 mg twice daily)
Study: 35656851
Drug: Refill-based opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refill-based opioid prescription method (experimental arm)
Study: 35656851
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (single prescription for all postoperative narcotics)
Study: 32665040
Drug: Lopinavir (400mg)
Normalized name: Lopinavir
DrugBank: Lopinavir (DB01601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lopinavir (400mg) / Ritonavir (100mg) twice daily for 10 days
Study: 32665040
Drug: Hydroxychloroquine (800mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (800mg on Day 1, followed by 400mg twice a day for 6 days)
Study: 33628403
Drug: Lower limb
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower limb joint nursing and rehabilitation system based on intelligent medical treatment
Study: 34075872
Drug: Antibiotic prescribing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prescribing for respiratory tract diagnoses (RTDs)
Study: 34075872
Drug: Family medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family medicine versus internal medicine
Study: 38700630
Drug: 14-day bismuth-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day bismuth-containing quadruple therapy
Study: 35636341
Drug: TPM (metronomic
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPM (metronomic oral cyclophosphamide + Trastuzumab + Pertuzumab)
Study: 33750355
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic Acid (FA) supplementation 400 μg/day from the 14th gestational week
Study: 34032286
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of rEPO (loading dose 2000 IU, infusion at 520 IU/h) from 6 to 72 h post-asphyxia
Study: 34032286
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline or 5000 IU rEPO, with repeated doses every 48 h for 5 days
Study: 35778620
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) treatment for 7 days
Study: 33212205
Drug: Multicomponent behavioral
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent behavioral intervention program including fluid intake prescription and adaptive behavioral interventions (financial incentives, structured problem solving, automated adherence interventions)
Study: 33028243
Drug: Integrated GP
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated GP care plus treatment as usual
Study: 35398241
Drug: 3 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg/day Zataria multiflora extract
Study: 35398241
Drug: 6 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg/day Zataria multiflora extract
Study: 34486305
Drug: KCl 0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: KCl 0.45 g/polybag + T. asperellum 30 g/polybag (K3)
Study: 34486305
Drug: KCl 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: KCl 0.15 g/polybag + T. asperellum 50 g/polybag (K1)
Study: 34486305
Drug: KCl 0.30
Approvals — FDA: no, EMA: no, PMDA: no
Description: KCl 0.30 g/polybag + T. asperellum 40 g/polybag (K2)
Study: 34486305
Drug: KCl 0.60
Approvals — FDA: no, EMA: no, PMDA: no
Description: KCl 0.60 g/polybag + T. asperellum 20 g/polybag (K4)
Study: 34486305
Drug: KCl 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: KCl 0.75 g/polybag + T. asperellum 10 g/polybag (K5)
Study: 35730664
Drug: Oral methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate (MTX) at a full dose of 0.3 mg/kg/week (maximum 25 mg/week) for 12 weeks
Study: 35730664
Drug: Subcutaneous methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous methotrexate (MTX) at a full dose of 0.3 mg/kg/week (maximum 25 mg/week) for 12 weeks
Study: 34147090
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of infants with hemodynamically significant PDA (hsPDA)
Study: 36093907
Drug: L-arginine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (8 g/d for 7 days)
Study: 35694030
Drug: Curcumin (4000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (4000 mg daily)
Study: 34034690
Drug: ADVANCE intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADVANCE intervention + substance use treatment as usual (TAU), n=54
Study: 616191660
Drug: Compression Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression Therapy (CT)
Study: 33960119
Drug: mirabegron 50
Normalized name: mirabegron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mirabegron 50 mg QD
Study: 33960119
Drug: solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: solifenacin 5 mg QD
Study: 34519141
Drug: Aerolizer® with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerolizer® with 200 µg salbutamol
Study: 34519141
Drug: Handihaler® with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Handihaler® with 200 µg salbutamol
Study: 33948712
Drug: Lenvatinib (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib (8 mg/day for < 60 kg; 12 mg/day for ≥ 60 kg)
Study: 34780022
Drug: SGLT-2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT-2 inhibitors (dapagliflozin 10 mg or empagliflozin 10 mg)
Study: 34780022
Drug: Guideline-directed medical
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-directed medical therapy
Study: 34479930
Drug: Retrorectus mesh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrorectus mesh augmentation with lightweight polypropylene mesh
Study: 36151932
Drug: 6-implant group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-implant group
Study: 33092415
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (GnRH-A)
Study: 34604251
Drug: Huashibaidu granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huashibaidu granule 10 g twice daily
Study: 33337109
Drug: Conventional energy
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional energy drink (ED1) containing carbohydrates and 3 mg·kg‐1 of caffeine
Study: 33337109
Drug: Sugar-free energy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-free energy drink (ED2) containing 3 mg·kg‐1 of caffeine
Study: 32429429
Drug: Cod residual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cod residual protein (Cod-RP) 8.1 g/day for eight weeks
Study: 33856613
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (0-120 IU of NovoLog) with exercise
Study: 33856613
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (0-120 IU of NovoLog) with sitting control
Study: 32591295
Drug: HF nurse
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HF nurse titration
Study: 32591295
Drug: HF cardiologist
Approvals — FDA: no, EMA: no, PMDA: no
Description: HF cardiologist titration
Study: 32894967
Drug: Polypill (hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill (hydrochlorothiazide 12.5 mg, aspirin 81 mg, atorvastatin 20 mg, and either enalapril 5 mg or valsartan 40 mg)
Study: 32569090
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (ITMO)
Study: 34843940
Drug: Nivolumab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (240 mg/body) administered every 2 weeks for up to 52 cycles
Study: 34388561
Drug: SSRIs alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs alone (drug group)
Study: 33096986
Drug: Treatment effect
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment effect modeling methods
Study: 33096986
Drug: Optimal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal treatment regime methods
Study: 36457360
Drug: Video-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video-based cognitive behavioral therapy (CBT), 10 sessions over 12 weeks with a licensed clinical psychologist, using iPads via Apple FaceTime.
Study: 32216621
Drug: Group-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based cognitive hypnotherapy (8 sessions, weekly)
Study: 33127212
Drug: Dexamethasone iontophoresis
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone iontophoresis (1 mg dexamethasone per 1 g administered under the active electrode, intensity of 0.1–0.2 mA/cm2 for ten days)
Study: 35321938
Drug: Over-the-scope-clips (OTSC)
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over-the-scope-clips (OTSC) therapy
Study: 35321938
Drug: Standard endoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard endoscopic treatment
Study: 33514384
Drug: Canola oil
Normalized name: Canola Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canola oil (25 g/day)
Study: 33514384
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (25 g/day)
Study: 33514384
Drug: Sunflower oil
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower oil (25 g/day)
Study: 34563236
Drug: Dopamine agonists
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonists (DA) treatment
Study: 32390545
Drug: Usual Treatment
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Treatment (Control)